Tramadol

CMAJ. Canadian Medical Association Journal

Volumn 185, Issue 8, 2013, Pages

  Young, James W S ^a   Juurlink, David N ^b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CARBAMAZEPINE; CODEINE; CYTOCHROME P450 2D6; GABAPENTIN; O NORTRAMADOL; PLACEBO; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ANALGESIC ACTIVITY; APNEA; CANADA; DRUG DEPENDENCE; DRUG EFFECT; DRUG FATALITY; DRUG MECHANISM; DRUG METABOLISM; GENOTYPE; HUMAN; NEUROPATHIC PAIN; OSTEOARTHRITIS; PAIN; PRACTICE GUIDELINE; SEIZURE; SEROTONIN SYNDROME; SHORT SURVEY; WITHDRAWAL SYNDROME;

EID: 84877893638     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.121592     Document Type: Article

References (6)

1. Leppert W. CYP2D6 in the metabolism of opioids for mild to moderate pain. Pharmacology 2011;87:274-85.
2. Kahan M, Mailis-Gagnon A, Wilson L, et al. Canadian guideline for safe and effective use of opioids for chronic noncancer pain; clinical summary for family physician. Part 1: general population. Can Fam Physician 2011;57:1257-66.
3. Cepeda MS, Camargo F, Zea C, et al. Tramadol for osteoarthritis [review]. Cochrane Database Syst Rev 2006;(3):CD005522.
4. Duehmke RM, Hollingshead J, Cornblath DR. Tramadol for neuropathic pain [review]. Cochrane Database Syst Rev 2006;(3):CD003726.
5. Hassanian-Moghaddam H, Farajidana H, Sarjami S, et al. Tramadol-induced apnea. Am J Emerg Med 2013;31:26-31.
6. Senay EC, Adams EH, Geller A, et al. Physical dependence on Ultram® (tramadol hydrochloride): both opioid-like and atypical withdrawal symptoms occur. Drug Alcohol Depend 2003;69:233-41. (Pubitemid 36293935)